Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

COVID-19 GPH|Home|PHGKB Last data update: Jun 17, 2021 . (Total: 21634 Documents since 2020)

Last Posted: Jun-17-2021 12:10:08
spot light Spotlight

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
C Liu et al, Cell, June 16, 2021

We study the ability of monoclonal antibodies, convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2 and complement this with structural analyses of Fab/RBD complexes and map the antigenic space of current variants. Neutralization of both viruses is reduced when compared with ancestral Wuhan related strains but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2 suggesting that individuals previously infected by these variants may be more susceptible to reinfection by B.1.617.2.

What is CDC doing to track SARS-COV-2 variants?
CDC, June 17, 2021

In the United States, CDC tracks emerging variants through genomic surveillance with the following approaches: Leading the National SARS-CoV-2 Strain Surveillance (NS3) system; Partnering with commercial diagnostic laboratories; Collaborating with universities; Supporting state, territorial, local and tribal health departments; Leading the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance (SPHERES) consortium.

Digital health: balancing innovation and cybersecurity
Lancet Respiratory Medicine editorial, June 16, 2021

Digital health is an area of medicine that has seen huge acceleration and investment globally over the past decade—even more so during the COVID-19 pandemic, when reliance on digital and telehealth has been essential. With this growth in digital health, however, comes concern surrounding the use of digital patient data and the associated risks of cybersecurity breaches.

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
X Shen et al, NEJM, June 17, 2021

The modestly lower value in neutralization titers against the B.1.429 variant seen in this study is similar to that we saw previously when neutralization of the B.1.1.7 variant was tested with the same assay using serum samples obtained from recipients of the mRNA-1273 and NVX-CoV2373 vaccines.4 These results, and the high efficacy shown by these vaccines, suggest that vaccine-elicited neutralizing antibodies are likely to remain effective against the B.1.429 variant. The magnitude of resistance seen with the B.1.351 variant is of greater concern with respect to current vaccines.

news Latest News and Publications
The delta variant is a rising threat in the U.S. We have to redouble vaccination efforts.
AK Jha, The Washington Post, June 16, 2021

New Added Today

Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
Toback S, et al. medRxiv, Jun 13, 2021.

New Added Today

A Top Virologist in China, at Center of a Pandemic Storm, Speaks Out
Qin A, Buckley C. New York Times, Jun 14, 2021.

New Added Today

Spike D614G - A Candidate Vaccine Antigen Against Covid-19.
Koenig Paul-Albert et al. The New England journal of medicine 2021 6 (24) 2349-2351

New Added Today

How the COVID pandemic is changing global science collaborations
Maher B, Van Noorden R. Nature, Jun 16, 2021.

New Added Today

CureVac, latest experimental coronavirus vaccine, proved just 47 percent effective amid spread of variants, preliminary analysis shows
Johnson CY. Washington Post, Jun 16, 2021.

New Added Today

Controlling the pandemic during the SARS-CoV-2 vaccination rollout
J Viana et al, Nat Comms, June 16, 2021

New Added Today

A Novel and Expanding SARS-CoV-2 Variant, B.1.1.318, dominates infections in Mauritius
H Tegally et al, MEDRXIV, June 16, 2021

New Added Today

Evaluation of saliva molecular point of care for detection of SARS-CoV-2 in ambulatory care
JL Goff et al, MEDRXIV, June 16, 2021

New Added Today

Artificial neural network and logistic regression modelling to characterize COVID-19 infected patients in local areas of Iran.
Mohammadi Farzaneh, et al. Biomedical journal 2021 0 0.

New Added Today

All Latest

About COVID-19 GPH

COVID-19 GPH is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that captures emerging discoveries and applications of genomics, molecular and other precision medicine and precision public health tools in the investigation and control of COVID-19. Contents include PubMed records via an automated pubmed search algorithm, preprint records from NIH iCite, the relevant information from many media sources picked by experts, and linkages to contents from our curated PHGKB databases.

Genomics Precision Health (GPH): The use of pathogen and human genomics and advanced molecular detection methods in discovery, clinical and public health investigations and response to COVID-19.
Non Genomics Precision Health (non-GPH): The use of big data, data science, digital health, machine learning and predictive analytic methods (not involving genomics) in discovery, clinical and public health investigations and response to COVID-19

Following categories are annotated by LitCovid from NCBI NIH.
MechanismUnderlying cause(s) of covid-19 infections and transmission & possible drug mechanism of action
Transmission Characteristics and modes of covid-19 transmissions, such as human-to-human
DiagnosisDisease assessment through symptoms, test results, and radiological features
PreventionPrevention, control, response and management strategies
Case ReportDescriptions of specific patient cases
ForecastingModelling and estimating the trend of covid-19 spread

Following categories are annotated by the text mining tool from CDC PHGKB
Health EquityRelevant to health equity. Search terms are derived from a list provided by the Association for Territorial Health Officials which include terms such as diversity, health disparities, and others.
VaccineRelevant to vaccine development, evaluation, implementation and impact. For additional information on vaccines and COVID-19. Check out general CDC Information pages
VariantRelevant to SARS-CoV-2 variants and their impact on public health. For additional information on variants COVID-19. Check out CDC New Variants of the Virus that Causes COVID-19 page
SurveillanceRelevant to SARS-CoV-2 public health surveillance and tracking. For additional information on COVID-19 surveillance, check out CDC COVID-19 Data Tracker

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.